Testing effectiveness (Phase 2)Study completedNCT05298254
What this trial is testing
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
Who this might be right for
Herpes Simplex
GlaxoSmithKline 505